Effect of rosuvastatin treatment on plasma visfatin levels in patients with primary hyperlipidemia

European Journal of Pharmacology

Volumn 578, Issue 2-3, 2008, Pages 249-252

  Kostapanos, Michael S ^a   Derdemezis, Christos S ^a   Filippatos, Theodosios D ^a   Milionis, Haralampos J ^a   Kiortsis, Dimitrios N ^a   Tselepis, Alexandros D ^b   Elisaf, Moses S ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Adipokine; Hyperlipidemia; Rosuvastatin; Visfatin

Indexed keywords

ROSUVASTATIN; VISFATIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; FEMALE; HUMAN; HYPERLIPIDEMIA; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; BIOLOGICAL MARKERS; CYTOKINES; DOWN-REGULATION; FEMALE; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; LIFE STYLE; LIPIDS; MALE; MIDDLE AGED; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PILOT PROJECTS; PYRIMIDINES; SULFONAMIDES; TIME FACTORS; TREATMENT OUTCOME;

EID: 37349012116     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2007.09.019     Document Type: Article

References (19)

1. Chen M.P., Chung F.M., Chang D.M., Tsai J.C., Huang H.F., Shin S.J., and Lee Y.J. Elevated plasma levels of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 91 (2006) 295-299
2. Dahl T.B., Yndestad A., Skjelland M., Oie E., Dahl A., Michelsen A., Damås J.K., Tunheim S.H., Ueland T., Smith C., Bendz B., Tonstad S., Gullestad L., Frøland S.S., Krohg-Sørensen K., Russell D., Aukrust P., and Halvorsen B. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation 115 (2007) 972-980
3. Filippatos T.D., Derdemezis C.S., Kiortsis D.N., Tselepis A.D., and Elisaf M.S. Increased plasma levels of visfatin/pre-B cell colony enhancing factor in obese and overweight patients with primary metabolic syndrome. J. Endocrinol. Investig. 30 (2007) 323-326
4. Filippatos, T.D., Derdemezis, C.S., Gazi, I.F., Lagos, K., Kiortsis, D.N., Tselepis, A.D., Elisaf, M.S., in press. Increased plasma visfatin levels in subjects with metabolic syndrome. Eur. J. Clin. Invest.
5. Fukuhara A., Matsuda M., Nishizawa M., Segawa K., Tanaka M., Kishimoto K., Matsuki Y., Murakami M., Ichisaka T., Murakami H., Watanabe E., Takagi T., Akiyoshi M., Ohtsubo T., Kihara S., Yamashita S., Makishima M., Funahashi T., Yamanaka S., Hiramatsu R., Matsuzawa Y., and Shimomura I. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307 (2005) 426-430
6. Grundy S.M., Cleeman J.I., Merz C.N., Brewer Jr. H.B., Clark L.T., Hunninghake D.B., Pasternak R.C., Smith Jr. S.C., Stone N.J., National Heart, Lung, and Blood Institute, American College of Cardiology Foundation, and American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110 (2004) 227-239
7. Haider D.G., Pleiner J., Francesconi M., Wiesinger G.F., Müller M., and Wolzt M. Exercise training lowers plasma visfatin concentrations in patients with type 1 diabetes. J. Clin. Endocrinol. Metab. 91 (2006) 4702-4704
8. Kostapanos M.S., Liberopoulos E.N., Goudevenos J.A., Mikhailidis D.P., and Elisaf M.S. Do statins have an antiarrhythmic activity?. Cardiovasc. Res. 75 (2007) 10-20
9. Liberopoulos E.N., Daskalopoulou S.S., Mikhailidis D.P., Wierzbicki A.S., and Elisaf M.S. A review of the lipid-related effects of fluvastatin. Curr. Med. Res. Opin. 21 (2005) 231-243
10. Mauser W., Perwitz N., Meier B., Fasshauer M., and Klein J. Direct adipotropic actions of atorvastatin: differentiation state-dependent induction of apoptosis, modulation of endocrine function, and inhibition of glucose uptake. Eur. J. Pharmacol. 564 (2007) 37-46
11. Milionis H.J., Rizos E., Kostapanos M., Filippatos T.D., Gazi I.F., Ganotakis E.S., Goudevenos J., Mikhailidis D.P., and Elisaf M.S. Treating to target patients with primary hyperlipidaemia: comparison of the effects of ATOrvastatin and ROSuvastatin (the ATOROS study). Curr. Med. Res. Opin. 22 (2006) 1123-1131
12. Moschen A.R., Kaser A., Enrich B., Mosheimer B., Theurl M., Niederegger H., and Tilg H. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J. Immunol. 178 (2007) 1748-1758
13. Oki K., Koide J., Nakanishi S., Nakashima R., and Yamane K. Fenofibrate increases high molecular weight adiponectin in subjects with hypertriglyceridemia. Endocr. J. 54 (2007) 431-435
14. Ong H.T. The statin studies: from targeting hypercholesterolaemia to targeting the high-risk patient. QJM 98 (2005) 599-614
15. Pilz S., Mangge H., Obermayer-Pietsch B., and März W. Visfatin/pre-B-cell colony-enhancing factor: a protein with various suggested functions. J. Endocrinol. Investig. 30 (2007) 138-144
16. Samal B., Sun Y., Stearns G., Xie C., Suggs S., and McNiece I. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol. Cell. Biol. 14 (1994) 1431-1437
17. Sethi J.K., and Vidal-Puig A. Visfatin: the missing link between intra-abdominal obesity and diabetes?. Trends Mol. Med. 11 (2005) 344-347
18. Takebayashi K., Suetsugu M., Wakabayashi S., Aso Y., and Inukai T. Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes. Metabolism 56 (2007) 451-458
19. West of Scotland Coronary Prevention Study Group. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 97 (1998) 1440-1445